{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:08:26Z","timestamp":1792458506255,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013751\/1"],"award-info":[{"award-number":["MR\/N013751\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013751\/1"],"award-info":[{"award-number":["MR\/N013751\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515012623"],"award-info":[{"award-number":["2023A1515012623"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Extracellular-regulated protein kinase 5 (ERK5) is an emerging therapeutic target in cancer, and small-molecule ERK5 inhibitors have been widely employed to define its role in tumour biology. Here, we show that the commonly used ERK5 inhibitors XMD8-92 and JWG-045 suppress RSL3-induced ferroptosis in breast cancer cells, in contrast to the next-generation ERK5 inhibitors JWG-071 and BAY-885, and the MEK5 inhibitor BIX02189. Using CRISPR-mediated gene editing, we generated ERK5-deficient breast cancer cells and found that XMD8-92 and JWG-045 retained their anti-ferroptotic activity against RSL3 in the absence of ERK5 expression, indicating clear off-target effects. Pathway-level analysis of bulk RNA-sequencing data using FerrDb-curated gene sets revealed no global alteration in ferroptotic activity in BT474 cells following XMD8-92 treatment. Interestingly, XMD8-92 did not inhibit RSL3-induced lipid peroxidation and preserved cell viability even after RSL3-induced ferroptosis initiation. Based on these observations, we propose that XMD8-92 confers transient resistance to ferroptotic cell death by maintaining plasma membrane integrity, potentially through enhanced membrane repair mechanisms. Collectively, these findings reveal a previously unrecognised off-target anti-ferroptotic activity of XMD8-92 and JWG-045, further highlighting the limitation of these compounds for ERK5-specific mechanistic studies.<\/jats:p>","DOI":"10.1038\/s41598-026-42079-w","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:33:41Z","timestamp":1772271221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["XMD8-92 and JWG-045 exhibit anti-ferroptotic activities, independently of inhibiting ERK5"],"prefix":"10.1038","volume":"16","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmern","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan B.","family":"Pidd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gala","family":"Konteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zejia","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Butterworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Whitmarsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"42079_CR1","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.cellsig.2012.07.007","volume":"24","author":"G. N. Nithianandarajah-Jones","year":"2012","unstructured":"Nithianandarajah-Jones G. N. et al. ERK5: structure, regulation and function. Cell. Signal. 24, 2187\u20132196 (2012).","journal-title":"Cell. Signal."},{"key":"42079_CR2","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3390\/ijms20061426","volume":"20","author":"B - Stecca","year":"2019","unstructured":"Stecca, B. & Rovida, E. Impact of ERK5 on the Hallmarks of Cancer. Int. J. Mol. Sci. 20, 1426 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"42079_CR3","doi-asserted-by":"publisher","first-page":"e5565","DOI":"10.1371\/journal.pone.0005565","volume":"4","author":"JC - Montero","year":"2009","unstructured":"Montero, J. C. et al. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One. 4, e5565 (2009).","journal-title":"PLoS One"},{"key":"42079_CR4","doi-asserted-by":"publisher","first-page":"11308","DOI":"10.18632\/oncotarget.2324","volume":"5","author":"MJ Ortiz-Ruiz","year":"2014","unstructured":"Ortiz-Ruiz, M. J. et al. Therapeutic potential of ERK5 targeting in triple negative breast cancer. Oncotarget 5, 11308\u201311318 (2014).","journal-title":"Oncotarget"},{"key":"42079_CR5","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1038\/s41388-021-01798-2","volume":"40","author":"Q - Xu","year":"2021","unstructured":"Xu, Q. et al. The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion. Oncogene 40, 3929\u20133941 (2021).","journal-title":"Oncogene"},{"key":"42079_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1158\/2767-9764.CRC-21-0089","volume":"2","author":"J - Zhang","year":"2022","unstructured":"Zhang, J. et al. Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1\/S cell cycle transition. Cancer Res. Commun. 2, 131\u2013145 (2022).","journal-title":"Cancer Res. Commun."},{"key":"42079_CR7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3390\/ijms21030929","volume":"21","author":"AJ - Pearson","year":"2020","unstructured":"Pearson, A. J. et al. Discovery of a Gatekeeper Residue in the C-Terminal Tail of the Extracellular Signal-Regulated Protein Kinase 5 (ERK5). Int. J. Mol. Sci. 21, 929 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"42079_CR8","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1016\/j.bbagen.2012.11.020","volume":"1830","author":"R Brigelius-Floh\u00e9","year":"2013","unstructured":"Brigelius-Floh\u00e9, R. & Maiorino, M. Glutathione peroxidases. Biochim. Biophys. Acta. 1830, 3289\u20133303 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"42079_CR9","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.bmcl.2011.09.047","volume":"22","author":"M - We\u00efwer","year":"2012","unstructured":"We\u00efwer, M. et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg. Med. Chem. Lett. 22, 1822\u20131826 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"42079_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS - Yang","year":"2014","unstructured":"Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317\u2013331 (2014).","journal-title":"Cell"},{"key":"42079_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41589-020-0501-5","volume":"16","author":"JK - Eaton","year":"2020","unstructured":"Eaton, J. K. et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat. Chem. Biol. 16, 497\u2013506 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"42079_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X - Jiang","year":"2021","unstructured":"Jiang, X., Stockwell, B. R. & Conrad, M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell. Biol. 22, 266\u2013282 (2021).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"42079_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS - Viswanathan","year":"2017","unstructured":"Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453\u2013457 (2017).","journal-title":"Nature"},{"key":"42079_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ - Hangauer","year":"2017","unstructured":"Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247\u2013250 (2017).","journal-title":"Nature"},{"key":"42079_CR15","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/s41556-024-01464-1","volume":"26","author":"A - Schwab","year":"2024","unstructured":"Schwab, A. et al. Zeb1 mediates EMT\/plasticity-associated ferroptosis sensitivity in cancer cells by regulating lipogenic enzyme expression and phospholipid composition. Nat. Cell. Biol. 26, 1470\u20131481 (2024).","journal-title":"Nat. Cell. Biol."},{"key":"42079_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molmed.2020.01.006","volume":"26","author":"DM - Pereira","year":"2020","unstructured":"Pereira, D. M. & Rodrigues, C. M. P. Targeted Avenues for Cancer Treatment: The MEK5-ERK5 Signaling Pathway. Trends Mol. Med. 26, 394\u2013407 (2020).","journal-title":"Trends Mol. Med."},{"key":"42079_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ccr.2010.08.008","volume":"18","author":"Q - Yang","year":"2010","unstructured":"Yang, Q. et al. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 18, 258\u2013267 (2010).","journal-title":"Cancer Cell."},{"key":"42079_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1021\/ml100304b","volume":"2","author":"X - Deng","year":"2011","unstructured":"Deng, X. et al. Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1. ACS Med. Chem. Lett. 2, 195\u2013200 (2011).","journal-title":"ACS Med. Chem. Lett."},{"key":"42079_CR19","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.cellsig.2012.08.001","volume":"24","author":"D Perez-Madrigal","year":"2012","unstructured":"Perez-Madrigal, D., Finegan, K. G., Paramo, B. & Tournier, C. The extracellular-regulated protein kinase 5 (ERK5) promotes cell proliferation through the down-regulation of inhibitors of cyclin dependent protein kinases (CDKs). Cell. Signal. 24, 2360\u20132368 (2012).","journal-title":"Cell. Signal."},{"key":"42079_CR20","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1038\/onc.2012.332","volume":"32","author":"Q - Yang","year":"2013","unstructured":"Yang, Q. et al. BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction. Oncogene 32, 3156\u20133164 (2013).","journal-title":"Oncogene"},{"key":"42079_CR21","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/gutjnl-2014-306761","volume":"64","author":"E - Rovida","year":"2015","unstructured":"Rovida, E. et al. The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut 64, 1454\u20131465 (2015).","journal-title":"Gut"},{"key":"42079_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/0008-5472.CAN-13-3043","volume":"75","author":"KG - Finegan","year":"2015","unstructured":"Finegan, K. G. et al. ERK5 is a critical mediator of inflammation-driven cancer. Cancer Res. 75, 742\u2013753 (2015).","journal-title":"Cancer Res."},{"key":"42079_CR23","doi-asserted-by":"publisher","first-page":"ra86","DOI":"10.1126\/scisignal.aaa3206","volume":"8","author":"K - Wilhelmsen","year":"2015","unstructured":"Wilhelmsen, K. et al. Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation. Sci. Signal. 8, ra86 (2015).","journal-title":"Sci. Signal."},{"key":"42079_CR24","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.celrep.2016.07.033","volume":"16","author":"CA - Williams","year":"2016","unstructured":"Williams, C. A. et al. Erk5 Is a Key Regulator of Naive-Primed Transition and Embryonic Stem Cell Identity. Cell. Rep. 16, 1820\u20131828 (2016).","journal-title":"Cell. Rep."},{"key":"42079_CR25","doi-asserted-by":"publisher","first-page":"11865","DOI":"10.1073\/pnas.1609019113","volume":"113","author":"EC - Lin","year":"2016","unstructured":"Lin, E. C. et al. ERK5 kinase activity is dispensable for cellular immune response and proliferation. Proc. Natl. Acad. Sci. U S A. 113, 11865\u201311870 (2016).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"42079_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ejmech.2013.10.052","volume":"70","author":"X Deng","year":"2013","unstructured":"Deng, X. et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur. J. Med. Chem. 70, 758\u2013767 (2013).","journal-title":"Eur. J. Med. Chem."},{"key":"42079_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.canlet.2014.05.011","volume":"351","author":"SM - Sureban","year":"2014","unstructured":"Sureban, S. M. et al. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Lett. 351, 151\u2013161 (2014).","journal-title":"Cancer Lett."},{"key":"42079_CR28","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41467-020-15031-3","volume":"11","author":"PA - Lochhead","year":"2020","unstructured":"Lochhead, P. A. et al. Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nat. Commun. 11, 1383 (2020).","journal-title":"Nat. Commun."},{"key":"42079_CR29","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1021\/acschembio.7b00638","volume":"13","author":"J - Wang","year":"2018","unstructured":"Wang, J. et al. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chem. Biol. 13, 2438\u20132448 (2018).","journal-title":"ACS Chem. Biol."},{"key":"42079_CR30","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1021\/acs.jmedchem.8b01606","volume":"62","author":"D - Nguyen","year":"2019","unstructured":"Nguyen, D. et al. Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5. J. Med. Chem. 62, 928\u2013940 (2019).","journal-title":"J. Med. Chem."},{"key":"42079_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.canlet.2021.07.007","volume":"519","author":"W - Zhao","year":"2021","unstructured":"Zhao, W. et al. Inhibition of MEK5\/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis. Cancer Lett. 519, 141\u2013149 (2021).","journal-title":"Cancer Lett."},{"key":"42079_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bbrc.2008.09.087","volume":"377","author":"RJ - Tatake","year":"2008","unstructured":"Tatake, R. J. et al. Identification of pharmacological inhibitors of the MEK5\/ERK5 pathway. Biochem. Biophys. Res. Commun. 377, 120\u2013125 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"42079_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/A:1006331716981","volume":"58","author":"L - Flanagan","year":"1999","unstructured":"Flanagan, L., Van Weelden, K., Ammerman, C., Ethier, S. P. & Welsh, J. SUM-159PT cells: a novel estrogen independent human breast cancer model system. Breast Cancer Res. Treat. 58, 193\u2013204 (1999).","journal-title":"Breast Cancer Res. Treat."},{"key":"42079_CR34","doi-asserted-by":"publisher","first-page":"D571","DOI":"10.1093\/nar\/gkac935","volume":"51","author":"N - Zhou","year":"2023","unstructured":"Zhou, N. et al. FerrDb V2: update of the manually curated database of ferroptosis regulators and ferroptosis-disease associations. Nucleic Acids Res. 51, D571\u2013D582 (2023).","journal-title":"Nucleic Acids Res."},{"key":"42079_CR35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1042\/BST20110663","volume":"40","author":"PA - Lochhead","year":"2012","unstructured":"Lochhead, P. A., Gilley, R. & Cook, S. J. ERK5 and its role in tumour development. Biochem. Soc. Trans. 40, 251\u2013256 (2012).","journal-title":"Biochem. Soc. Trans."},{"key":"42079_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbrc.2019.11.110","volume":"522","author":"E - Dai","year":"2020","unstructured":"Dai, E., Meng, L., Kang, R., Wang, X. & Tang, D. ESCRT-III-dependent membrane repair blocks ferroptosis. Biochem. Biophys. Res. Commun. 522, 415\u2013421 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"42079_CR37","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/s41418-020-00691-x","volume":"28","author":"L - Pedrera","year":"2021","unstructured":"Pedrera, L. et al. Garc\u00eda-S\u00e1ez AJ. Ferroptotic pores induce Ca2+ fluxes and ESCRT-III activation to modulate cell death kinetics. Cell. Death Differ. 28, 1644\u20131657 (2021).","journal-title":"Cell. Death Differ."},{"key":"42079_CR38","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1038\/s41388-018-0270-8","volume":"37","author":"S - Pavan","year":"2018","unstructured":"Pavan, S. et al. A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis. Oncogene 37, 4197\u20134213 (2018).","journal-title":"Oncogene"},{"key":"42079_CR39","doi-asserted-by":"publisher","first-page":"101046","DOI":"10.1016\/j.tranon.2021.101046","volume":"14","author":"AB - Bhatt","year":"2021","unstructured":"Bhatt, A. B. et al. Diverse and converging roles of ERK1\/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer. Transl Oncol. 14, 101046 (2021).","journal-title":"Transl Oncol."},{"key":"42079_CR40","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nprot.2010.43","volume":"5","author":"L - Young","year":"2010","unstructured":"Young, L., Sung, J., Stacey, G. & Masters, J. R. Detection of Mycoplasma in cell cultures. Nat. Protoc. 5, 929\u2013934 (2010).","journal-title":"Nat. Protoc."},{"key":"42079_CR41","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.chembiol.2011.05.010","volume":"18","author":"CV - Miduturu","year":"2011","unstructured":"Miduturu, C. V. et al. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem. Biol. 18, 868\u2013879 (2011).","journal-title":"Chem. Biol."},{"key":"42079_CR42","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI - Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"42079_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.6026\/97320630002005","volume":"2","author":"L - Kumar","year":"2007","unstructured":"Kumar, L. & Futschik, E. Mfuzz: a software package for soft clustering of microarray data. Bioinformation 2, 5\u20137 (2007).","journal-title":"Bioinformation"},{"key":"42079_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S - H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."},{"key":"42079_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA - Byers","year":"2013","unstructured":"Byers, L. A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279\u2013290 (2013).","journal-title":"Clin. Cancer Res."},{"key":"42079_CR46","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1038\/s41388-025-03459-0","volume":"44","author":"W - Zhang","year":"2025","unstructured":"Zhang, W. et al. NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibition. Oncogene 44, 2929\u20132941 (2025).","journal-title":"Oncogene"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42079-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42079-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42079-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:05:59Z","timestamp":1781636759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42079-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42079"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42079-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11337"}}